2,971 publications from this institution
Metabolic syndrome has been associated with an increased risk of various cancers. A multicenter study conducted in Italy and Switzerland on 3,869 cases of breast cancer in post-menopause reported a relative risk of 1.75 in women with the metabolic syndrome, confirming the results of other smaller epidemiological studies.
2nd ed.
The relationship between use of non-contraceptive oestrogens and risk of breast cancer was investigated using data from a hospital-based case-control study from Northern Italy. This study covered 1,108 patients with histologically confirmed breast cancers and 1,281 control subjects with a large spectrum of acute conditions unrelated to any of the known or suspected risk factors for breast cancer. Compared with "never-users", the age-adjusted relative risk for "ever-users" was 1.93 (95% confidence interval = 1.35-2.75). The risk increased with duration of use (relative risk = 2.08 for over 2 years), but was unrelated to time elapsed since first or last use. Allowance for a large number of identified potential confounding factors, including indicators of socio-economic status and the major determinants of breast cancer risk, failed to account for the observed association (multivariate relative risk = 1.84 for ever use and 2.04 for greater than 2 year use). Possible explanations for these findings and for their apparent discrepancy with some American data are discussed in terms of different baseline incidence of breast cancer in the two populations, and hence of potential baseline differences in availability of endogenous serum oestrogens. Nonetheless, the results of this study should be interpreted cautiously and viewed as a further contribution to a topic still open to debate.
Death certification rates from 17 non-sexual and 4 sexual cancers were used to examine patterns of correlation between various cancers within the 20 Italian regions. A large number of strongly positive correlations emerged, reflecting the geographical distribution of cancer mortality in Italy which shows substantially higher rates for several common sites in northern areas. The most notable findings were the high positive correlations between various tobacco-related cancers in both sexes (however somewhat higher in males), the positive correlations between most intestinal sites and between a well defined group of other cancers including intestines in both sexes, breast and ovary in females and prostate in males, previously described in several widely heterogeneous populations. Various alcohol-related cancers showed high positive coefficients in males but not in females. Several suggestions which emerged from previous correlation studies but which generally lacked convincing biological or epidemiological consistency were not confirmed by the present data. Conversely, a few strong correlations emerged in the present study which are not explainable in terms of available knowledge of the causes of cancer, or obvious confounding. Though probably incidental, the existence of these correlations between cancers with widely heterogeneous or largely undefined etiology is still an indirect indication that these neoplasms are largely avoidable, since it is unlikely that the same genetic determinants are strongly associated with such different malignancies.
Generic products are not responsible for the high rate of discontinuation from antihypertensive drug therapy. Assuming therapeutic equivalence, clinical implication is of prescribing generic drug therapies.